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Abstract
Background: Uncovering novel components of signal transduction pathways and their interactions within species is a
central task in current biological research. Orthology alignment and functional genomics approaches allow the effective
identification of signaling proteins by cross-species data integration. Recently, functional annotation of orthologs was
transferred across organisms to predict novel roles for proteins. Despite the wide use of these methods, annotation of
complete signaling pathways has not yet been transferred systematically between species.
Principal Findings: Here we introduce the concept of ‘signalog’ to describe potential novel signaling function of a protein
on the basis of the known signaling role(s) of its ortholog(s). To identify signalogs on genomic scale, we systematically
transferred signaling pathway annotations among three animal species, the nematode Caenorhabditis elegans, the fruit fly
Drosophila melanogaster, and humans. Using orthology data from InParanoid and signaling pathway information from the
SignaLink database, we predict 88 worm, 92 fly, and 73 human novel signaling components. Furthermore, we developed an
on-line tool and an interactive orthology network viewer to allow users to predict and visualize components of orthologous
pathways. We verified the novelty of the predicted signalogs by literature search and comparison to known pathway
annotations. In C. elegans, 6 out of the predicted novel Notch pathway members were validated experimentally. Our
approach predicts signaling roles for 19 human orthodisease proteins and 5 known drug targets, and suggests 14 novel
drug target candidates.
Conclusions: Orthology-based pathway membership prediction between species enables the identification of novel
signaling pathway components that we referred to as signalogs. Signalogs can be used to build a comprehensive signaling
network in a given species. Such networks may increase the biomedical utilization of C. elegans and D. melanogaster.I n
humans, signalogs may identify novel drug targets and new signaling mechanisms for approved drugs.
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Introduction
Signal transduction pathways are involved in the control of
various cellular processes, including cell growth, proliferation,
differentiation and stress response in divergent animal phyla [1].
In humans, dysregulation of signaling systems has been implicated
in diverse pathologies, such as cancer, neuronal degeneration,
muscle atrophy, immune deficiency and diabetes [2]. To
understand better the physiological and pathological roles of
signaling pathways, one should generate a comprehensive
signaling map (network) that ideally contains all components of
distinct signaling pathways and their genetic and physical
interactions. Currently, studies in model organisms ranging from
invertebrates to mammals are increasingly used to create such a
network [3]. The effort to map novel signaling components and
interactions has largely benefited from network alignment
techniques and other widely used functional genomics methods,
allowing the integration of functional data both among and within
species [4,5]. For example, recent publications applied large-scale
data integration and machine learning techniques to predict gene
function, including signaling pathways in D. melanogaster [6,7].
Most of these methods predict new gene or protein properties
(annotations) on the basis of sequence homology and similarities
between known functions. Similar annotation transfer approaches
have been applied to predict structural properties (e.g., domain
composition), expression profiles, and physical interactions for
thousands of proteins [8–10]. For predicting interactions, for
example, the network-based concept of ‘‘interologs’’ has been
suggested: two proteins are predicted to physically interact, if their
orthologs interact in another organism [11]. Interologs, however,
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reliable than interactions generated by high-throughput (HTP)
approaches [13]. A clear definition of interologs and their
applicability to estimate the reliability of HTP experiments
[14,15] have been found to be useful in expanding protein
interaction networks [12,16–18]. The concept of interologs has
been extended to ‘‘regulogs’’, which can be identified by an
orthology-based prediction of a regulatory interaction between a
protein (i.e., a transcription factor) and a corresponding DNA
sequence (i.e., a transcription factor binding site). In addition,
recently, ‘‘phenologs’’ were used as predictors of disease-associated
genes in model organisms [19].
In large-scale analyses, protein-protein interaction data are
usually obtained from HTP experiments, such as yeast two-hybrid
screens. However, the low abundance of extracellular, membrane-
bound and nuclear signaling components (e.g., ligands, receptors,
and transcription factors) makes these experimental techniques
only moderately efficient for identifying signaling interactions.
Accordingly, several signaling pathway databases have been
created manually by collecting relevant data from the literature
[20]. However, so far most of them lack those key features (e.g.,
uniform pathway curation across more than one species) that
would be necessary for transferring signaling pathway membership
information between species. Reliable and detailed signaling
pathway databases are crucial for signaling predictions because
they are needed (1) as sources of known pathway information from
which the predictions can be performed (i.e., seed data) and (2) as
reference data sets against which the novelty of the predictions can
be tested (i.e., those predicted signaling pathway member proteins
that are already known pathway members should be removed
from the list of predictions, while all others can be regarded as
predicted components). Steps towards these goals have been taken,
e.g., by Reactome [21], where pathway curation is standardized
and human signaling functions are transferred from other species.
Further steps could be (i) to compare predictions with already
published experimental evidence in target species, (ii) to predict
signaling reactions in other species, and (iii) to use a database that
explicitly allows orthology-based predictions for pathway compo-
nents between organisms. A recent, comprehensive pathway
resource from our lab, SignaLink, applies uniform curation rules
to keep the levels of details to be identical in all examined
pathways for C. elegans, D. melanogaster and humans [22]. Moreover,
the structure of the SignaLink dataset allows the systematic
transfer of pathway annotations between two species on the basis
of sequence orthology.
Interestingly, in two different organisms the same signaling
pathway is often known at different levels of detail. This may be
due to evolutionary divergence or to differences between the
current coverage of the two organisms’ interaction maps.
Therefore, large-scale pathway annotation transfer between these
3 organisms can extend our current knowledge of their signaling
pathways. Note that in cases of rapid evolution, orthology-based
predictions are less reliable as even the orthologs exist, they no
longer participate in the same signaling pathway [23].
The topology of signaling pathways is important for selecting
possible novel drug target candidates [24]. As an example, drugs
used for inhibiting a specific signaling protein in order to affect
proliferation may actually activate the pathway by triggering an
unknown negative feedback loop [25]. Transferring signaling
pathway annotations across species may alleviate such difficulties
and can provide a more comprehensive signaling network.
Identification of novel signaling components may help to discover
drug targets as (i) these signaling components can increase the
applicability of model organisms for testing drugs and drug target
candidates, (ii) in humans, they can serve as potential novel drug
targets, and (iii) in the case of already used target proteins they can
help to uncover possible side-effects.
Here we introduce the concept of ‘signalog’ to predict a protein
as a novel component of a signaling pathway based on the
signaling pathway membership of its ortholog in another
organism. We identify signalogs on genomic scale in 8 signaling
pathways, including the MAPK, TGF-b, and WNT pathways (for
a complete list, see the Methods) from 3 intensively investigated
species: C. elegans, D. melanogaster and humans, and verify their
novelty and predictive power, using both bioinformatics and
experimental methods. We also show the utility of the signalog
concept in drug target discovery.
Methods
Source of signaling components and interactions
To predict a role for a protein (i.e. provide a successful
annotation), the quality of the original sources from which the
annotation transfer (prediction) can be performed is crucial. The
original pathway data, including the lists of proteins of 8 distinct
signaling pathways and their interactions were obtained from the
SignaLink database (http://www.signalink.org) [22]. The 8
pathways examined in this study were the EGF/MAPK
(epidermal growth factor/mitogen activated protein kinase),
TGF-b (transforming growth factor-beta), insulin/IGF-1 (insu-
lin-like growth factor-1), Notch, WNT/Wingless, Hedgehog,
JAK/STAT (Janus activating kinase/signal transducer and
activator of transcription), and NHR (nuclear hormone receptor)
pathways. The basic properties of the SignaLink database are as
follows: the components of the 8 pathways in C. elegans, D.
melanogaster,a n dH. sapiens were compiled by applying uniform
curation rules to keep the level of detail identical for all pathways
examined; proteins were assigned to pathways based on literature
data; and interactions were listed manually from original
publications presenting biochemical evidence [22]. Note that
the lower number of pathways in SignaLink, compared to other
sources, is largely due to its more precise pathway definition rules.
This approach avoids artificial grouping and reduces the number
of pathways without reducing the numbers of proteins and
interactions. (For an extensive comparison and benchmarking,
see the [22].) Note that SignaLink uses more than 20 reviews per
each pathway to list pathway components, in contrast to the
average 5–15 reviews per a pathway in other resources [22]. The
structure of SignaLink allows the systematic transfer of pathway
annotations between two species on the basis of sequence
orthology (see the next section).
Orthology assignment for identifying signalogs
Sequence-based approaches, also in combination with interac-
tion networks, have been frequently applied to detect orthology
relationships between proteins [26,27]. For example, the tool
PathBLAST aligns an ordered list of proteins or pathways on the
basis of their ortholog relations [28]. In the Clusters of
Orthologous Groups (COG) database, orthologous groups are
defined through reciprocal best BLAST matches between proteins
from at least three species [29,30]. Furthermore, sequence
clustering techniques incorporate a range of BLAST scores (not
only the absolute best hits) and can achieve a higher sensitivity
[31]. One of these techniques, InParanoid [31], distinguishes
between outparalogs, i.e., homologous sequences that emerged by
duplication before speciation, and inparalogs that emerged after
speciation. Compared to outparalogs, inparalogs are more likely to
share functions. InParanoid incorporates the entire list of BLAST
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compared organisms into orthologous clusters [31]. Each cluster
contains proteins with related sequences from the two species, and
each protein has an Inparalog score (for the calculation of this
score, see [31]).
Previously, during the compilation of the SignaLink database,
InParanoid data (version 6.1) were applied to find known signaling
proteins by orthology searches [22,31]. Based on SignaLink, now
we can link a protein with a previously unknown signaling role to a
signaling system, if the protein has an ortholog as a clearly
identified component of a signaling pathway in another organism.
For a protein with more than one ortholog (according to its
InParanoid orthologous cluster), we used only those orthologs that
have an Inparalog score higher than 0.3. To confirm that signalogs
have no previously identified signaling interactions, we checked
them with the protein-protein interaction search engines iHOP
and ChiliBot [32,33].
Orthology-based pathway annotation transfer
In each of the three species examined (C. elegans, D. melanogaster,
and H. sapiens), we listed those proteins that have no known
signaling interactions but have at least one signaling pathway
member ortholog in the other two species. Similarly to the concept
of functional orthology [26], for each of these proteins we assumed
that their pathway annotations (i.e., signaling role) can be
transferred between species. In other words, we predicted that
such a protein is a member of the signaling pathway(s) to which its
ortholog(s) in the organism belong(s). These proteins were termed
as signalog proteins (signalogs). Note also that in SignaLink [22] a
protein can belong to more than one pathway. Thus, a signalog
can also be annotated to more than one pathway. Figure 1 shows
the workflow of our analysis.
Verifying the novelty of signalog predictions
To verify the novelty of signalog predictions, i.e., the predicted
signaling roles have not been known or predicted in other
resources yet, we have (i) searched the literature with semi-
automated methods for already known annotations, (ii) compared
the list of signalogs and their predicted pathway memberships to
known pathway annotations in pathway databases, and also (iii)
compared the ortholog predictions to previously published
interolog predictions.
To grade the novelty of signalogs (signaling pathway annota-
tions) and quantify the confidence level of each prediction, we
performed semi-automated searches using PubMed, UniProt, GO,
Wormbase, FlyBase, iHOP, and Chilibot web services [32–37].
During this process, direct manual curation and Python scripts
checking multiple proteins in one webservice were used. In each of
the 3 species examined, we classified the predicted signalogs into 5
groups on the basis of their known properties in the literature: (1)
no orthology information and/or no biochemical function is
available; (2) there are known orthologs with unknown biochem-
ical function; (3) orthology information: unknown, biochemical
function: known; (4) known orthologs with known biochemical
function(s); (5) known orthologs with known biochemical function
and already known pathway annotation(s). Categories 1 to 5
denote a decreasing level of novelty. However, even category (5)
contains signalogs for which at least one novel signaling pathway
membership is predicted. Furthermore, to check the novelty of the
predicted signaling pathway memberships, we compared the list of
Figure 1. Workflow of pathway annotation transfer for predicting the signaling roles of proteins in C. elegans, D. melanogaster, and
humans. The lists of signaling proteins and their interactions were obtained from the SignaLink database ([22], http://signalink.org). Orthology
assignment was performed between each pair of the 3 species. Proteins were predicted to be members of the same signaling pathway(s) where their
orthologs belong.
doi:10.1371/journal.pone.0019240.g001
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pathway membership annotations from Reactome and KEGG
[21,38].
Next, we applied interologs to verify the novelty of our ortholog
predictions. (An interolog is a pair of proteins predicted to interact
based on the interaction of the two proteins’ orthologs in at least
one other organism [11].) To reveal the presence of signalogs in
current orthology-based prediction databases, we compared
already identified interologs in worms, flies, and humans using 3
species-specific datasets (WI8, DroID, and HomoMINT)
[12,39,40] with interologs generated from SignaLink data. Neither
SignaLink [22] nor the current signalog identification approach
identify interologs directly, thus we used an indirect method. First,
we deduced interologs from SignaLink data by linking two
proteins in an organism, if their orthologs interact in at least one
other of the three organisms. After generating all possible
interologs from SignaLink, we examined only those interologs
(predicted interactions) in which at least one of the interactors is a
signalog protein (predicted signaling pathway member).
Experimental validation of signalogs
We confirmed experimentally the predicted signaling pathway
memberships (signaling roles) of 6 signalogs. Out of the 21 Notch
signalogs in C. elegans, we selected 6 genes (aqp-6, D1009.3, nsh-1,
num-1, F10D7.5 and crb-1) that have no paralogs, i.e., homologs in
the same organism. These genes encode diverse proteins: their
orthologs in the other two species include receptors, co-factors,
and transcription factors (Table 1). Neither literature search (in
PubMed) nor interaction searches in STRING 8.0 [14] provided
experimental evidence for the signaling role of these proteins in the
C. elegans Notch pathway. To validate that the selected 6 signalogs
indeed function in the Notch signaling pathway, we tested whether
they genetically interact with lin-12, which encodes a worm Notch
receptor [41].
Wild-type strain was used as Bristol N2 [42]. The other strains
used in this study were RB676 num-1(ok433)V, FX02407 aqp-
6(tm2407)V, RB1267 D1009.3(ok1349)X, RB1011 crb-1(ok931)X,
and MT2343 dpy-19(e1259)III lin-12(n137)III/unc-32(e189)III lin-
12(n137n720)III. The allele n137 is a gain-of-function mutation in
lin-12, which confers ectopic vulval induction in mutant
hermaphrodites. These lin-12(n137) mutant animals exhibit a
Multivulva (Muv) phenotype (the mutants possess 2–6 vulval
protrusions, whereas wild-type hermaphrodites have normally one
vulval structure, which does not protrudes from the ventral surface
of the body). Strains were cultured as described previously [43].
For the selected genes that are not yet characterized mutationally
and for lin-12, we applied RNA interference- (RNAi) based gene
downregulation. For RNAi, 0.9 kbp (nsh-1) - 1.0 kbp long
(F10D7.5) cDNA fragments were amplified by RT-PCR, and
were cloned into the vector pPD129.36. The constructs were then
transformed into E. coli HT115. RNAi experiments were
performed as described [43]. Control strains were fed with
HT115 bacteria expressing the empty RNAi vector. The following
forward and reverse primers were used. For nsh-1:5 9-GGC TTT
AAT GGC TTC ACG AG-39 and 59-AAG GAA GAA CTG
TCG CTT GC-39, for F10D7.5:5 9-AAG CGT TGA TCC GTA
GAC ATC-39 and 59-TCG AGA TTG ACG AGA ACG TG-39,
and for lin-12:5 9-CGC TTC ATA TTG GCT CAT GTC-39 and
59-CCA GCT TCG CAT TTA TTA TTC AC-39.
As num-1(ok433), aqp-6(tm2407) D1009.3(ok1349), and crb-
1(ok931) single mutant animals looked superficially wild-type, we
treated these mutant animals with lin-12 double-stranded RNA
(dsRNA), and the average number of vulval protrusions were
determined at their young adulthood. lin-12(gf) mutant animals
were also treated with nsh-1 or F10D7.5 dsRNA, and tested for the
penetrance and expressivity of the Muv phenotype. The
significance of results was tested with Chi square tests.
Functional annotation of signalog proteins
To examine the drug target relevance of the predicted signaling
pathway member proteins, we downloaded additional information
from DAVID [44], and disease-related data from OMIM, GAD
and Orthodisease [45–47]. Protein domain information was
extracted from InterPRO (drug-protein interactions are based on
structural properties) [48]. Functional and cellular compartment
data were obtained from GO [49]. The list of currently used drug
targets was downloaded from DrugBank (version 2.5) [50].
Results
Computational prediction and analysis of novel signaling
components
We identified novel signaling pathway components based on the
signaling pathway memberships of orthologs in another organism.
We found 88, 92, and 73 proteins in C. elegans, D. melanogaster and
H. sapiens, respectively, which had previously not been assigned to
Table 1. Experimentally validated signalogs and their orthologs.
Selected signalogs
(gene name)
ORFs
(WormBase ID) Mutant allele
Signalog
class
Known
signaling
ortholog in fly
Known signaling
ortholog in human
Role of the
ortholog in the
Notch pathway
aqp-6 C32C4.2 lf mutant: (tm2407)V 3 bip - co-factor
crb-1 F11C7.4 lf mutant: (ok931)X 3 crb NOTCH2 receptor
D1009.3 D1009.3 lf mutant: (ok1349)X 1 sca - co-factor
F10D7.5 F10D7.5 no characterized mutant
alleles
4 neur NEURL transcription factor,
co-factor
nsh-1 F20H11.2 no characterized mutant
alleles
2 sno SBNO1 transcription factor
num-1 T03D8.1 lf mutant: (ok433)V 4 numb NUMB co-factor
We experimentally validated 6 novel Notch pathway components in C. elegans. 4 of them have been characterized by at least one loss-of-function mutant allele. None of
these mutations caused altered morphology, behavior, or survival, i.e., these mutant animals appear superficially wild-type. Fly and human orthologs are also listed.
Signalogs are classified into 5 groups (signalog classes) based on their known properties (see Methods and Fig. 3a). In the SignaLink database, each protein is annotated
with one or more pathway role (e.g., co-factor, receptor).
doi:10.1371/journal.pone.0019240.t001
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species that is clearly associated with a signaling pathway. We
hypothesized that these 253 proteins function in the same signaling
pathways as their orthologs. Thus, we named the predicted
signaling components signalog proteins, or briefly signalogs. Note
that in contrast to an interolog, a signalog is a single protein (not
an interacting pair) that has an ortholog annotated to a signaling
pathway. In the three species examined our in silico approach
predicted 301 novel signaling pathway annotations in total (39 of
the 253 signalogs were assigned to more than one signaling
pathway). For the complete list of the predicted signalog proteins
and their pathway annotations, see Table S1.
After a detailed analysis of the predicted pathway annotations of
signalogs, we found that in each of the three species the EGF/
MAPK pathway contains the largest portion of signalogs (25% of
the signalogs in the in worm, 42.5% in the fly and 28.6% in
humans), which is consistent with the fact that this pathway
contains the highest number of signaling components [22] (see also
Fig. 2). Interestingly, in C. elegans a similarly high number of
signalogs was predicted as a potential Hedgehog component (29
proteins; 25.9%). Note that a canonical Hh pathway has not been
identified in C. elegans due to specific gene loss [1]. Our present
study and previous analyses however show that several compo-
nents of the canonical Hedgehog pathway are present in this
organism [1]. In flies a large portion of signalogs appears in the
WNT and TGF-b pathways, whereas in humans, several signalogs
were associated with the WNT, Notch and Hedgehog pathways
(for details, see Fig. 2). Beside pathway membership predictions,
we placed the signaling orthologs into a wiring diagram of
signaling networks. This network can be examined with an
interactive ortholog network viewer (described below).
Next, we tested the concept of orthology-based pathway
annotation transfer by testing whether known signaling proteins
have known signaling pathway member orthologs. We analyzed
the three organisms separately. For each organism we listed all
signaling pathway proteins from SignaLink and then listed, with
InParanoid (version 6.1) [31], all orthologs of these signaling
proteins in the other two species. We found at least one ortholog in
the other two species for 93.4% (worm), 81.6% (fly), and 64.8%
(humans) of all signaling proteins and we found that 83.2%,
67.5%, and 82.6% of these orthologs indeed participate in a
signaling pathway. Thus, a high portion (77.8% on average) of
known signaling proteins has at least one ortholog with a known
signaling function in the other two organisms. Moreover, on
average 67.8% of signaling pathway member proteins have at least
one ortholog in the other two species with an identical pathway
membership. These high ratios underscore the relevance of our
orthology-based signaling component prediction.
Verifying the novelty of predictions
To examine the novelty of the predicted signaling roles and to
quantify their confidence levels, we first classified these predicted
proteins into 5 groups on the basis of their known properties.
These groups range from genes for which only the ORF is known
to genes whose protein products have known molecular function(s)
(for details see the Methods and Fig. 3a). In each of the three
organisms examined, we found only one protein already known as
a signaling pathway component; for these three proteins we
predicted additional (novel) pathway annotations. In C. elegans and
D. melanogaster, most signalogs (55.7% and 58.7% of all,
respectively) have not yet been characterized biochemically, while
in humans, only 26% of the signalogs remain uncharacterized.
Note that this lower rate is partly due to the larger abundance of
literature information on signaling in humans compared to worms
and flies (Chi square test, p,0.0001). Taken together, we conclude
that signalog prediction can effectively contribute to the
identification of novel signaling components.
Next, we verified that our signolog predictions are novel in the
sense that the predicted signaling roles have not been known or
predicted by other resources yet. We compared the list of signalogs
and their predicted pathway memberships to known pathway
membership annotations from KEGG and Reactome databases.
Note that the KEGG database contains pathway data for all three
species examined, while Reactome database contains only human
data [21,38]. For C. elegans, D. melanogaster and H. sapiens, we found
23, 19 and 35 signalog proteins, respectively, already present in
KEGG, i.e., 20%, 26%, and 47% of all signalogs in the three
organisms. From these proteins only 11, 5 and 15, respectively –
i.e., 13.3% on average – were assigned to the same pathway in
KEGG as in our prediction. Reactome contains 16 of the listed
Figure 2. Statistical analysis of signalogs. The number of predicted novel signaling pathway components (signalogs) in each pathway for the
three species examined. The total number of signalogs in each species is shown in parentheses. Although we predicted a total of 253 signalogs, this
statistical comparison contains 301 novel pathway components, because 39 signalog proteins were assigned to more than one pathway (these 39
had a total of 87 pathway annotations).
doi:10.1371/journal.pone.0019240.g002
Identification of Novel Signaling Pathway Proteins
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in our prediction. We conclude that, depending on the organism
and the database, 20 to 47% of all signalog proteins are already
present in KEGG or Reactome, however, the large majority
(86.7%) of pathway memberships we predicted for them are novel.
Finally, to reveal the presence of signalogs in current orthology-
based prediction databases, we used interologs (orthology-based
predicted interactions). We compared the interologs generated for
this test from the SignaLink dataset with the interologs listed for
worms, flies and humans by 3 species-specific databases (WI8,
DroID, and HomoMINT [12,39,40]) (see the Methods). We
examined only those interologs, where at least one of the
interactors is a signalog protein. We found that in worms, flies
and humans, respectively 34, 30, and 48 signalogs are present only
in the SignaLink dataset,indicating that a high portion of the
predicted proteins has not yet been investigated by this orthology-
Figure 3. Verification of the novelty of signalogs (protein – signaling pathway annotations). a) Classification of signalog proteins based
on their known properties in the literature found by manual curation and searches in PubMed, UniProt, GO, Wormbase, Flybase, iHOP, and Chilibot
[32–35]. b–c) Comparison of signalog and interolog data between Signalink and one of the WI8, DroID or HomoMINT databases. The signalog
proteins and possible interologs that are only present in SignaLink have not been predicted by previous orthology based (interolog) studies. This
underscores the novelty of the signalogs. For details on interologs predicted from SignaLink data, see the main text.
doi:10.1371/journal.pone.0019240.g003
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the 3 species-specific resources, we found 1028, 1338, and 465
interologs in worms, flies and humans, respectively. The overlap
between interologs generated from SignaLink and the interologs
from any of the other 3 databases was relatively low: 5.5% in
worms, 38.8% in flies and 12.5% in humans (Fig. 3b). Shared
interologs can be interpreted as already known orthology-based
predictions. A low number of overlapping interologs suggests that
most of our current signalog predictions are novel. The high
number of novel interologs is probably due to (i) the uniform
curation method used for compiling SignaLink for all three
species; (ii) the underrepresentation of signaling proteins in the
three species-specific interolog datasets [5% of all signaling
proteins in worms (WI8) and flies (DroID), and 2.8% in humans
(HomoMINT)]; and (iii) the stringency of the interolog filtering
algorithm HomoMINT [12]. We conclude that uniformly curated
data sources, such as SignaLink, can facilitate orthology-based
predictions.
While this study was in progress, Yan et al. predicted gene
function for Drosophila with a large-scale machine learning
technique [6]. 1121 genes were predicted to function in the same
pathways as those examined in our study. We performed an
additional test with this fly-specific dataset to quantify the novelty
of our predictions. (Note that Yan et. al. [6] listed the ErbB, JNK,
and MAPK pathways separately, following KEGG [38], however,
in SignaLink these (sub)pathways all belong to the EGF/MAPK
pathway in agreement with Ref. [1]). Out of the 92 fly signalogs
predicted by the current paper, only 27 genes are listed in this
large-scale study, i.e., two-thirds of all fly signalogs still remain
novel predicted signaling components. In the large-scale study of
Yan et. al. these shared 27 genes have 42 pathway annotations
(many of them belong to more than one pathway), while here we
predict 34 pathway annotations for them. 15 out of these pathway
annotations are identical (for 14 of the 27 shared genes).
Interestingly, a large-scale study predicted that p38b functions in
2 pathways (EGF/MAPK and TGF), while in our study 2
additional pathways (JAK/STAT and WNT) were predicted for
this gene. In conclusion, the small overlap of the predicted novel
signaling pathway genes and their predicted pathways verifies the
novelty of the signalogs listed in the current paper and the
predictive power of the method.
Experimental validation of Notch pathway member
signalogs in C. elegans
The Notch pathway controls cell growth, differentiation and
proliferation during normal animal development [51]; in humans,
aberrant Notch signaling has been implicated in various
pathologies such as cancer and neurodegeneration [52]. There-
fore, identifying novel Notch pathway components may have a
significant impact on developmental and biomedical research. To
test experimentally the relevance of our signalog predictions, we
assessed whether the genes that encode the 6 newly identified non-
paralogous Notch pathway components in C. elegans (aqp-6,
D1009.3, nsh-1, num-1, F10D7.5 and crb-1) genetically interact
with lin-12, which encodes a nematode Notch receptor (see Table 1
for further information on the selected 6 genes). lin-12 is a key
regulator of vulval patterning as it specifies the so-called (2u)
secondary vulval cell fate during pattering of this tissue [53]. Thus,
a genetic interaction between lin-12 and a selected signalog (gene)
would clearly indicate the participation of that gene in Notch
signaling.
During C. elegans vulval development, six originally equivalent
ventral epidermal cells, called vulval precursor cells [VPCs,
consecutively numbered as P(3–8).p], are specified into one of
three distinct – primary (1u), secondary (2u) or tertiary (3u) – vulval
cell fates by the combined action of different signaling systems,
including the Ras/MAPK, WNT, Notch and synMuv (for
synthetic Multivulva) pathways [54] (Fig. 4a). Recently, the
nematode sex determination pathway was also implicated in
vulval fate determination [55]. At the L3 larval stage, the inductive
Ras and WNT signaling cascades promote vulval fates in the three
central VPCs, P(5–7).p; descendants of these cells eventually form
the matured vulval tissue. A LIN-12/Notch-mediated lateral signal
emitted from P6.p specifies 2u fates by attenuating Ras signaling in
the adjacent VPCs, P(5,7).p [41,56]. An inhibitory signal mediated
by the synMuv genes antagonizes Ras signaling to repress vulval
fates in each VPC [57]. As a result of these inductive, lateral and
inhibitory signaling events, P6.p adopts a primary (1u) vulval fate,
while its adjacent VPCs, P(5,7).p, adopt secondary (2u) vulval fates.
The non-induced VPCs, P(3,4,8).p, adopt non-vulval tertiary (3u)
fates. In wild-type hermaphrodites, P(3–8).p always adopt the 3u-
3u-2u-1u-2u-3u stereotypical pattern of vulval fates.
Perturbation of signals specifying vulval fates often results in a
visible mutant vulval phenotype. Inactivation of lin-12 causes a
Protruded vulva (Pvl) phenotype that is due to the misspecification
of 2u vulval cells; in lin-12 loss-of-function (lf) mutant hermaph-
rodites each induced VPC [P(5–7.p] adopts a 1u fate (Fig. 4b),
whereas lin-12 gain-of-function (gf) mutations confer VPCs [P(3–
8).p] to adopt 2u fates, resulting in multiple vulval protrusions, i.e.,
a Multivulva phenotype (Muv) (Fig. 4c).
To reveal whether the 6 selected C. elegans Notch signalogs
(Table 1) indeed function in this pathway, we first treated aqp-6, crb-
1, num-1, and D1009.3 loss-of-function mutant animals with lin-12
dsRNA, and monitored the penetrance of the Pvl phenotype,
compared to control lin-12(RNAi) animals. We found that lin-12
RNAi treatment of wild-type animals cause a Pvl phenotype with
17% penetrance. As compared, lin-12 RNAi in aqp-6, crb-1, num-1,
and D1009.3 single loss-of-function mutant background significant-
ly increased the penetrance of the Pvl phenotype (Fig. 4d). Note that
these single mutants treated with control RNAi (empty vector)
displayed a superficially wild-type (non-Muv) vulval morphology.
We next treated lin-12 gain-of-function mutant animals with
nsh-1 or F10D7.5 dsRNA (these two genes have not yet been
characterized by mutant alleles) and monitored the average
number of vulval protrusions, compared to those found in lin-
12(gf) animals expressing the control RNAi alone. Of these lin-
12(gf) mutants, 93% were Muv and the number of vulval
inductions was 3.27+/20.19. The penetrance and expressivity of
the Muv phenotype in lin-12(gf) mutants was reduced by nsh-1 or
F10D7.5 RNAi treatment. Depletion of NSH-1 decreased the
penetrance of the Muv phenotype to 83%, whereas silencing of
F10D7.5 reduced it to 81%. Both RNAi interventions significantly
reduced the effect of lin-12 hyperactivity on vulval induction
(Fig. 4e). In summary, we found that all 6 selected genes
significantly alter vulval induction in lin-12(RNAi) animals and
lin-12(gf) mutants (for results, see Fig. 4; for statistics, see Text S1).
Thus, all 6 genes genetically interact with lin-12 and may
participate in Notch signaling. Note that these genetic interactions
between the 6 tested genes and the worm Notch receptor may be
indirect. Further, in depth biochemical studies are needed to
uncover the details of these connections, the actual roles of the 6
encoded proteins in the Notch pathway, and their roles in other
pathways involved in vulval formation.
On-line prediction and visualization tool for orthologous
signaling networks
To facilitate the adaptability of the signalog prediction concept,
we developed an on-line tool. This tool is available at http://
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presented in this study. After selecting the target species of our
prediction (worm, fly, or human), the user can enter a search
term (arbitrary protein or gene name/ID). The on-line tool
understands a variety of names and IDs, and also name
fragments. Next, an integrated UniProt API synonym search
helps the user to select the actual protein [34]. The selection of
the protein is followed by an ortholog search in the InParanoid
Figure 4. Experimental validation of 6 Notch pathway member signalogs in C. elegans. a) During normal C. elegans vulval development,
the pattern of vulval precursor cells is determined by the combined action of distinct signaling pathways, including the Ras/MAPK, Wnt, Notch, and
synMuv systems. Activations and inhibitions are represented with normal or blunted arrows. AC: anchor cell. Ras signaling activity is graded along its
relative distance from the AC cell (displayed with thick, thin, and dotted red lines). b) Protruded vulva (Pvl, main panel) and wild-type vulva (N2)
(inset). c) Ectopic vulval protrusions (arrows) and a normal vulval structure (dotted arrow) in a Muv animal. d) Penetrance of Pvl and normal vulval
phenotypes in loss-of-function mutant animals treated with lin-12 RNAi. In each case the mutation significantly increases the penetrance of Pvl
phenotype. e) Average number of vulval inductions in lin-12(gf) mutant animals treated with nsh-1 or F10D7.5 RNAi. Observe that both nsh-1 RNAi and
F10D7.5 RNAi have smaller numbers of vulvae than the control strain, lin-12(gf). Asterisks denote statistically significant differences. For details of the
statistics, see Text S1.
doi:10.1371/journal.pone.0019240.g004
Identification of Novel Signaling Pathway Proteins
PLoS ONE | www.plosone.org 8 May 2011 | Volume 6 | Issue 5 | e19240Figure 5. Snapshot of the Notch pathway visualized with the ortholog network viewer. This figure displays a subset of the C. elegans
Notch pathway with selected predicted pathway member proteins and their properties. This image includes multiple snapshots taken from the
interactive ortholog viewer available at http://signalink.org. Links representing interactions with direct and indirect evidence are displayed as normal
and dashed line styles, respectively. Activations (and inhibitions) are represented with normal (and blunted) arrows.
doi:10.1371/journal.pone.0019240.g005
Table 2. Novel signaling roles of signalogs relevant for drug target discovery.
Signalog
Predicted signaling
pathway Known as the target of the following drug(s)
Drug target-like
relevance score
ANPRA WNT Erythrityl Tetranitrate, Isosorbide Dinitrate, Isosorbide
Mononitrate, Nesiritide, Nitric Oxide, Nitroglycerin,
Nitroprusside
4
CASK EGF/MAPK Formic Acid 4
INSRR IGF/insulin - 3
MARK2 EGF/MAPK, WNT - 3
ABL2 Notch Adenosine Triphosphate, Dasatinib 2
AP2A2 Notch - 2
AQP8 Notch - 2
AUXILIN Notch - 2
B3GL1 Notch - 2
BMP2K Notch - 2
EDD1 Hedgehog - 2
FZD6 WNT - 2
GNAZ EGF/MAPK - 2
PIK3R2 IGF/insulin - 2
PTPRB EGF/MAPK - 2
STK24 WNT - 2
UGDH Hedgehog Nadide 2
YWHAB WNT - 2
NDST1 Hedgehog Adenosine-39-59-Diphosphate 1
Predicted signaling roles of human signalog proteins that are relevant in drug target discovery. The list of drug target proteins was downloaded from DrugBank [50].
The relevance score (for being a drug target) is the number of properties out of the following 4: membrane protein, enzymes, protein has a kinase domain, and disease-
relatedness (see Fig. 6 and the main text for details). The list of human signalogs and their drug target relevance scores are available in Table S2.
doi:10.1371/journal.pone.0019240.t002
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other 2 species. Next, the pathway memberships of the orthologs
are shown, and the user can select a pathway of interest.
Currently, the tool uses only SignaLink pathway data. If other
sources become available with uniform pathway curation across
all curated species and pathways, which is crucial for proper
pathway annotation transfer between species, the on-line tool is
capable to include these resources as well. In the last step, a
pathway membership prediction is performed for the queried
protein. If the queried protein is not known to be a member of
the examined pathway, then it is a signalog of that pathway. The
result is presented with a confidence score and a newly developed
visualization tool.
Despite the relatively large number of currently available
interaction visualization tools [58], only few visualize known and
predicted proteins and/or interactions in parallel. The viewer of
the MINT database is one such example [12]. This viewer displays
interactions predicted from model organisms, but not from
humans. Note that MINT [12] is a general protein-protein
interaction database containing significantly less signaling pathway
information than analyzed here. We developed an interactive
ortholog network viewer available at http://signalink.org and
http://signalink.org/signalog. This viewer can simultaneously
visualize known and predicted pathway membership information,
i.e., pathway annotation transfers (see snapshot in Fig. 5 as an
example), and allows the user to analyze, individually or together,
Table 3. Orthodisease proteins among signalogs in C. elegans.
Signalog Predicted pathway Human ortholog(s) Disease related to the human ortholog
ARR-1 EGF/MAPK, IGF/Insulin,
WNT, Hedgehog, Notch,
S-arrestin (SAG) Oguchi disease
LRP-1 Hedgehog, WNT Low-density lipoprotein receptor-related
protein 2 (LRP2)
Donnai-Barrow syndrome
PTC-1 Hedgehog Protein patched homolog 1 and 2
(PTC1, PTC2)
Basal cell nevus syndrome and
carcinoma,Holoprosencephaly7,Medulloblastoma
PTC-3 Hedgehog Protein patched homolog 3 (PTC3) Basal cell nevus syndrome and carcinoma,Holoprosencephaly7,
Medulloblastoma
CRB-1 Notch Crumbs homolog 1 and 2 (CRB1, CRB2) Pigmented paravenous chorioretinal atrophy, Retinis pigmentosa
PTP-2 EGF/MAPK, IGF/Insulin,
JAK/STAT
Tyrosine-protein phosphatase non-receptor
type 11 (SHP-2)
Leopard syndrome, Noonan syndrome, Juvenile myelomonocytic leukemia
WRT-1 Hedgehog Desert hedgehog protein (DHH) Indian
hedgehog protein (IHH) Sonic hedgehog
protein Precursor (SHH)
Gonadal dysgenesis, Brachydactyly, Acrocapitofemoral dysplasia,
Holoprosencephaly, Solitary median maxillary central incisor, Polydactyly,
Micropthalmia
TIG-3 TGF-b Transforming growth factor beta-3 (TGFB3),
Transforming growth factor beta-1 (TGFB1)
Arrhythmogenic ventricular dysplasia, Camurati-Engelmann disease
PAR-4 EGF/MAPK, WNT Serine/threonine-protein kinase 11 (STK11) Peutz-Jeghers syndrome, Testicular tumors
STA-1 JAK/STAT Signal transducer and activator of
transcription 1, 3, 4, 5b (STAT1, STAT3,
STAT4, STAT5b)
Growth hormone insensitivity, Hyperimmunoglobulin E recurrent infection,
Rheumatoid arthritis, Systemic lupus erythematosus, Atypical
Mycobacteriosis
The C. elegans signalog proteins that have one or more human ortholog(s) related to a disease (orthodisease proteins). Note that predicted components of Hedgehog
and JAK/STAT pathways are also present. The list of disease-related human proteins was downloaded from the Orthodisease database [46].
doi:10.1371/journal.pone.0019240.t003
Table 4. Orthodisease proteins among signalogs in D. melanogaster.
Signalog Predicted pathway Human ortholog(s)
Disease related to the human
ortholog
S6kII EGF/MAPK Ribosomal protein S6 kinase alpha-3 (RPS6KA3) Coffin-Lowry syndrome
Rab23 Hedgehog Ras-related protein 23 (RAB23) Carpenter syndrome
smt3 TGF-b Small ubiquitin-related modifier 4 (SUMO4) Diabetes mellitus
bonus TGF-b Transcription intermediary factor 1 (TRIM24), E3
ubiquitin-protein ligase (TRIM33)
Thyroid carcinoma
lkb1 EGF/MAPK, WNT Serine/threonine-protein kinase 11 (STK11) Peutz-Jeghers syndrome, Testicular
tumors
Pkc53E EGF/MAPK Protein kinase C gamma (PKCG) Spinocerebellar ataxia
tws EGF/MAPK Serine/threonine-protein phosphatase 2A (PPP2R2B) Spinocerebellar ataxia
Ror TGF-b, WNT Tyrosine-protein kinase transmembrane receptor (ROR2) Brachydactyly, Robinow syndrome
ELP1 EGF/MAPK Elongator complex protein 1 (IKBKAP) Hereditary sensory neuropathy
The D. melanogaster signalog proteins that have one or more human ortholog(s) related to a disease (orthodisease proteins). The list of disease-related human proteins
was downloaded from the Orthodisease database [46].
doi:10.1371/journal.pone.0019240.t004
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features of this signaling network viewer include zooming in/out
and panning possibilities, and switching the pathway view between
organisms. Proteins are hyperlinked to species-specific databases
and interactions are hyperlinked to the PubMed abstract of the
article(s) providing experimental evidence. Known signaling
pathway member proteins and signaling interactions are visualized
with colors different from predicted ones.
Supporting drug target discovery with signalogs
Signaling proteins are overrepresented among human disease
genes [2] and have been intensively studied as potential drug target
candidates [22,59]. According to DrugBank [50], only 5 (6.8%) out of
the 73 human signalog proteins identified here are currently
considered as drug targets (Table 2). Interestingly, the ratio of
disease-related proteins among human signalogs is much higher: 18
out of 73 (24.6%). The remaining 68 human signalog proteins not yet
implicated as drug targets may serve as further candidates (Table S2).
In C. elegans and D. melanogaster, only 44 and 58 orthologs of
human disease-related proteins (i.e., orthodisease proteins) have
beenannotatedtosignalingpathways,respectively[46].Inaddition,
we found pathway annotations for 10 (worm) and 9 (fly) additional
orthodisease proteins among signalogs (see Table 3 and Table 4 for
the lists of these proteins). For example, the human tyrosine-protein
phosphatase SHP-2 protein has a single worm ortholog, ptp-2,
which has not been annotated to any signaling pathway prior to our
current study. On the other hand, the role of SHP-2 in multiple
kinase pathways – including MAPK, JAK/STAT, and IGF – is well
established. Thus, identifying novel signaling components via their
orthologs may help future experimentation in model organisms and
the description of the underlying disease mechanism.
Finally, we tested the drug target relevance of human signalogs
by examining 4 key drug-related properties: disease-relatedness,
localization in the plasma membrane, enzymatic function, and
kinase domain content (see Fig. 6a) [60–62]. To analyze the drug
target related importance of the 73 human signalog proteins
identified, we first selected 2 proteins (ANPRA [P16066] and
CASK [O14936]) that have all 4 key properties (Fig. 6b). Both are
established drug targets which supports the relevance of our
analysis based on the 4 key properties. Our prediction suggests
signaling roles for ANPRA and CASK in the WNT and EGF/
MAPK pathways, respectively. We also predicted signaling roles
for 3 additional proteins already used as drug targets (ABL2
[P42684], UGDH [O60701], and NDST1 [P52848]) (Fig. 6b).
Novel pathway annotations of these drug targets are likely to
provide additional details about their mechanisms of action, enrich
therapeutic relevance, and warn of potential side effects. Following
the top scoring set we analyzed those 2 proteins, INSRR [P14616]
and MARK2 [Q7KZI7], that still have 3 of the 4 key properties,
but are currently not used as drug targets and are not known to be
disease-related. We predicted that INSRR functions in the IGF/
Insulin pathway, while MARK2 functions in both the EGF/
MAPK and Wnt pathways. Participation of MARK2 in more than
one pathway increases its relevance for drug target discovery
[22,63]. Table 2 lists the predicted signaling roles and drug target-
like properties for the most promising drug target candidates and
the drugs targeting the already used drug targets. The complete list
and drug target-like properties of signalogs can be found at http://
signalink.org and in Table S2.
Discussion
In our report we introduced a method for predicting novel
signaling pathway components, signalogs, in 3 species, based on
the signaling roles of their orthologs in other organisms. We
identified altogether 253 signalog proteins in two model organisms
– C. elegans and D. melanogaster – and humans. In addition, we
developed and on-line tool allowing the users to predict signalogs
and visualized known pathway data and predictions simultaneous-
ly with an ortholog network viewer. This viewer has distinctive
features that can facilitate the interactive (user-defined) investiga-
tion of orthologous signaling networks, and it can visualize the
predicted pathway components and their possible interactions,
leading to the establishment of additional signalogs in later updates
of the SignaLink database. The novelty of our predictions was
verified by analyzing key properties, known pathway annotations,
and already predicted interactions of signalogs. In C. elegans,w e
experimentally validated the signaling role of 6 predicted novel
Notch pathway proteins. We anticipate that signalogs and,
especially, orthodisease proteins of model organisms (see Table 3
and Table 4 and ref. [19]) can facilitate the design of novel, low
cost primary drug screens with fewer tests in vertebrates. Our
Figure 6. Analysis of signalogs as drug target candidates. a)
Numbers of membrane proteins (M), enzymes (E), proteins with a kinase
domain (K), and disease-related proteins (D) among signalog proteins
(control: all proteins of the SignaLink database). b) Numbers of
signalogs in the groups defined by the number of key properties out
of the listed 4 (M, E, K, and D). For each group, the number of drug
targets is shown separately. The names of the most promising drug
target candidate proteins and 2 already known drug targets (both do
have all 4 key properties) are listed. Table S2 lists all human signalog
proteins and their drug target relevance scores.
doi:10.1371/journal.pone.0019240.g006
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currently used drug target proteins and suggested 14 additional
proteins that can be used as novel drug target candidates, based on
their predicted pathway annotations and other properties (Table 2).
Our predictions may (i) reveal novel therapeutic intervention
points (e.g., the use of signalogs as novel targets to block specific
pathways); (ii) suggest novel applications of current drugs to
diseases, where the newly predicted signaling pathway of their
target is relevant, and (iii) help to identify possible side effects of
currently used drugs [59,64,65].
The identification of novel signaling components may have an
impact on various fields of biology. Extended signaling annotation
may allow a better explanation of unexpected mutant phenotypes
by linking the altered (signalog) gene to a signaling pathway with
known phenotypes. Biological research often focuses on altering
the function(s) of a single selected protein. However, this may
cause undesired dysregulation of a signaling pathway, interfere
with multiple cellular processes and lead to pleiotropic effects.
Therefore, constructing more comprehensive signaling networks
and identifying novel signaling components can certainly improve
the design and evaluation of experiments.
In the postgenomic era novel tools and methods are constantly
needed to integrate genomic information with cellular processes.
Current knowledge on signaling pathways is far from complete.
‘White spots’ can often be filled with the orthology-based transfer
of ‘complete’ signaling system annotations between species, for
example, by the method presented here. This method can be
effectively used for the prediction of novel signaling proteins. The
InParanoid database contains more than 100 eukaryotic genomes
and its downloadable algorithm can be applied to other genomes
as well, thus, orthology information is not a limiting factor for
signalog predictions. Currently, signalog predictions for other
genomes are limited mainly by the absence of proper signaling
pathway data sources. Most importantly, the curation rules of
databases should be uniform across all analysed organisms and
signaling pathways. Such databases would be essential for signalog
predictions both as seeds and as reference data sets. Unfortunately,
for species not yet listed in the SignaLink database, current
comprehensive signaling maps (databases) do not contain data
curated with these guidelines in sufficient quantities that would
allow the prediction of novel signaling components. The on-line
tool was designed such that extensions can be added easily and we
will include more species and pathways as soon as they become
available. Based on the results, examples, and experimental work
of this study, we believe that the predicted signaling pathway
memberships (signalogs) will be a good source of functional
hypotheses to be experimentally verified in all three investigated
organisms.
Supporting Information
Table S1 Predicted signaling pathway member proteins
(signalogs). Protein names, species-specific identifiers, UniProt
identifiers, and pathway annotations for all signalog proteins in the
three investigated species.
(XLS)
Table S2 List of human signalog proteins and their
drug target relevances. (1) Current drug target proteins and
their signaling roles predicted in the current paper. (2) Predicted
pathway annotations and further properties of proteins that are
possible novel drug targets.
(XLS)
Text S1 Experimental verification of signalog proteins.
Evaluation tables containing numerical experimental results and
p-values quantifying the significance of experimental results.
(PDF)
Acknowledgments
The authors thank C. Bo ¨de for help with the statistical evaluation; L.
Zsa ´kai and Z. Spiro for discussions and testing predictions, and two
anonymous reviewers for their comments.
Author Contributions
Conceived and designed the experiments: TK IJF TV. Performed the
experiments: TK PR IJF. Analyzed the data: TK IJF KL TV. Contributed
reagents/materials/analysis tools: MSS RP DF IJF. Wrote the paper: TK
IJF PC TV. Developed the on-line tool: MSS. Developed the ortholog
network viewer: RP.
References
1. Pires-daSilva A, Sommer RJ (2003) The evolution of signalling pathways in
animal development. Nat Rev Genet 4: 39–49.
2. Sakharkar MK, Sakharkar KR, Pervaiz S (2007) Druggability of human disease
genes. Int J Biochem Cell Biol 39: 1156–1164.
3. Beyer A, Bandyopadhyay S, Ideker T (2007) Integrating physical and genetic
maps: from genomes to interaction networks. Nat Rev Genet 8: 699–710.
4. Gabaldon T, Huynen MA (2004) Prediction of protein function and pathways in
the genome era. Cell Mol Life Sci 61: 930–944.
5. Kuzniar A, van Ham RC, Pongor S, Leunissen JA (2008) The quest for orthologs:
finding the corresponding gene across genomes. Trends Genet 24: 539–551.
6. Yan H, Venkatesan K, Beaver JE, Klitgord N, Yildirim MA, et al. (2010) A genome-
wide genefunction prediction resource for Drosophila melanogaster. PLoS One 5: e12139.
7. Costello JC, Dalkilic MM, Beason SM, Gehlhausen JR, Patwardhan R, et al.
(2009) Gene networks in Drosophila melanogaster: integrating experimental data to
predict gene function. Genome Biol 10: R97.
8. Yellaboina S, Dudekula DB, Ko MS (2008) Prediction of evolutionarily
conserved interologs in Mus musculus. BMC Genomics 9: 465.
9. Storm CE, Sonnhammer EL (2003) Comprehensive analysis of orthologous
protein domains using the HOPS database. Genome Res 13: 2353–2362.
10. Salgado D, Gimenez G, Coulier F, Marcelle C (2008) COMPARE, a multi-
organism system for cross-species data comparison and transfer of information.
Bioinformatics 24: 447–449.
11. Yu H, Luscombe NM, Lu HX, Zhu X, Xia Y, et al. (2004) Annotation transfer
between genomes: protein-protein interologs and protein-DNA regulogs.
Genome Res 14: 1107–1118.
12. Persico M, Ceol A, Gavrila C, Hoffmann R, Florio A, et al. (2005) HomoMINT:
an inferred human network based on orthology mapping of protein interactions
discovered in model organisms. BMC Bioinformatics 6 Suppl 4: S21.
13. Cusick ME, Yu H, Smolyar A, Venkatesan K, Carvunis AR, et al. (2009)
Literature-curated protein interaction datasets. Nat Methods 6: 39–46.
14. Jensen LJ, Kuhn M, Stark M, Chaffron S, Creevey C, et al. (2009) STRING 8–a
global view on proteins and their functional interactions in 630 organisms.
Nucleic Acids Res 37: D412–D416.
15. Li D, Liu W, Liu Z, Wang J, Liu Q, et al. (2008) PRINCESS, a protein
interaction confidence evaluation system with multiple data sources. Mol Cell
Proteomics 7: 1043–1052.
16. Brown KR, Jurisica I (2005) Online predicted human interaction database.
Bioinformatics 21: 2076–2082.
17. Kemmer D, Huang Y, Shah SP, Lim J, Brumm J, et al. (2005) Ulysses - an
application for the projection of molecular interactions across species. Genome
Biol 6: R106.
18. Huang TW, Tien AC, Huang WS, Lee YC, Peng CL, et al. (2004) POINT: a
database for the prediction of protein-protein interactions based on the
orthologous interactome. Bioinformatics 20: 3273–3276.
19. McGary KL, Park TJ, Woods JO, Cha HJ, Wallingford JB, et al. (2010)
Systematic discovery of nonobvious human disease models through orthologous
phenotypes. Proc Natl Acad Sci U S A 107: 6544–6549.
20. Bauer-Mehren A, Furlong LI, Sanz F (2009) Pathway databases and tools for
their exploitation: benefits, current limitations and challenges. Mol Syst Biol 5:
290.
21. Joshi-Tope G, Gillespie M, Vastrik I, D’Eustachio P, Schmidt E, et al. (2005)
Reactome: a knowledgebase of biological pathways. Nucleic Acids Res 33:
D428–D432.
22. Korcsmaros T, Farkas IJ, Szalay MS, Rovo P, Fazekas D, et al. (2010)
Uniformly curated signaling pathways reveal tissue-specific cross-talks and
support drug target discovery. Bioinformatics 26: 2042–2050.
Identification of Novel Signaling Pathway Proteins
PLoS ONE | www.plosone.org 12 May 2011 | Volume 6 | Issue 5 | e1924023. Beltrao P, Serrano L (2007) Specificity and evolvability in eukaryotic protein
interaction networks. PLoS Comput Biol 3: e25.
24. Chaudhuri A, Chant J (2005) Protein-interaction mapping in search of effective
drug targets. Bioessays 27: 958–969.
25. Sergina NV, Rausch M, Wang D, Blair J, Hann B, et al. (2007) Escape from
HER-family tyrosine kinase inhibitor therapy by the kinase-inactive HER3.
Nature 445: 437–441.
26. Bandyopadhyay S, Sharan R, Ideker T (2006) Systematic identification of
functional orthologs based on protein network comparison. Genome Res 16:
428–435.
27. Koonin EV (2005) Orthologs, paralogs, and evolutionary genomics. Annu Rev
Genet 39: 309–338.
28. Kelley BP, Yuan B, Lewitter F, Sharan R, Stockwell BR, et al. (2004)
PathBLAST: a tool for alignment of protein interaction networks. Nucleic Acids
Res 32: W83–W88.
29. Tatusov RL, Galperin MY, Natale DA, Koonin EV (2000) The COG database:
a tool for genome-scale analysis of protein functions and evolution. Nucleic Acids
Res 28: 33–36.
30. Altschul SF, Madden TL, Schaffer AA, Zhang J, Zhang Z, et al. (1997) Gapped
BLAST and PSI-BLAST: a new generation of protein database search
programs. Nucleic Acids Res 25: 3389–3402.
31. Berglund AC, Sjolund E, Ostlund G, Sonnhammer EL (2008) InParanoid 6:
eukaryotic ortholog clusters with inparalogs. Nucleic Acids Res 36: D263–D266.
32. Chen H, Sharp BM (2004) Content-rich biological network constructed by
mining PubMed abstracts. BMC Bioinformatics 5: 147.
33. Fernandez JM, Hoffmann R, Valencia A (2007) iHOP web services. Nucleic
Acids Res 35: W21–W26.
34. Boutet E, Lieberherr D, Tognolli M, Schneider M, Bairoch A (2007)
UniProtKB/Swiss-Prot: The Manually Annotated Section of the UniProt
KnowledgeBase. Methods Mol Biol 406: 89–112.
35. Ashburner M, Ball CA, Blake JA, Botstein D, Butler H, et al. (2000) Gene
ontology: tool for the unification of biology. The Gene Ontology Consortium
Nat Genet 25: 25–29.
36. Harris TW, Antoshechkin I, Bieri T, Blasiar D, Chan J, et al. (2010) WormBase:
a comprehensive resource for nematode research. Nucleic Acids Res 38:
D463–D467.
37. Drysdale R (2008) FlyBase: a database for the Drosophila research community.
Methods Mol Biol 420: 45–59.
38. Ogata H, Goto S, Sato K, Fujibuchi W, Bono H, et al. (1999) KEGG: Kyoto
Encyclopedia of Genes and Genomes. Nucleic Acids Res 27: 29–34.
39. Yu J, Pacifico S, Liu G, Finley RL, Jr. (2008) DroID: the Drosophila Interactions
Database, a comprehensive resource for annotated gene and protein
interactions. BMC Genomics 9: 461.
40. Simonis N, Rual JF, Carvunis AR, Tasan M, Lemmens I, et al. (2009)
Empirically controlled mapping of the Caenorhabditis elegans protein-protein
interactome network. Nat Methods 6: 47–54.
41. Greenwald I (2005) LIN-12/Notch signaling in C. elegans. WormBook. pp 1–16.
42. Brenner S (1974) The genetics of Caenorhabditis elegans. Genetics 77: 71–94.
43. Kamath RS, Ahringer J (2003) Genome-wide RNAi screening in Caenorhabditis
elegans. Methods 30: 313–321.
44. Huang dW, Sherman BT, Lempicki RA (2009) Systematic and integrative
analysis of large gene lists using DAVID bioinformatics resources. Nat Protoc 4:
44–57.
45. Amberger J, Bocchini CA, Scott AF, Hamosh A (2009) McKusick’s Online
Mendelian Inheritance in Man (OMIM). Nucleic Acids Res 37: D793–D796.
46. O’Brien KP, Westerlund I, Sonnhammer EL (2004) OrthoDisease: a database of
human disease orthologs. Hum Mutat 24: 112–119.
47. Becker KG, Barnes KC, Bright TJ, Wang SA (2004) The genetic association
database. Nat Genet 36: 431–432.
48. Hunter S, Apweiler R, Attwood TK, Bairoch A, Bateman A, et al. (2009)
InterPro: the integrative protein signature database. Nucleic Acids Res 37:
D211–D215.
49. Harris MA, Clark J, Ireland A, Lomax J, Ashburner M, et al. (2004) The Gene
Ontology (GO) database and informatics resource. Nucleic Acids Res 32:
D258–D261.
50. Wishart DS (2008) DrugBank and its relevance to pharmacogenomics.
Pharmacogenomics 9: 1155–1162.
51. Kimble J, Simpson P (1997) The LIN-12/Notch signaling pathway and its
regulation. Annu Rev Cell Dev Biol 13: 333–361.
52. Bolos V, Grego-Bessa J, de la Pompa JL (2007) Notch signaling in development
and cancer. Endocr Rev 28: 339–363.
53. Takacs-Vellai K, Vellai T, Chen EB, Zhang Y, Guerry F, et al. (2007)
Transcriptional control of Notch signaling by a HOX and a PBX/EXD protein
during vulval development in C. elegans. Dev Biol 302: 661–669.
54. Sternberg PW (2005) Vulval development. WormBook. pp 1–28.
55. Szabo E, Hargitai B, Regos A, Tihanyi B, Barna J, et al. (2009) TRA-1/GLI
controls the expression of the Hox gene lin-39 during C. elegans vulval
development. Dev Biol 330: 339–348.
56. Yoo AS, Bais C, Greenwald I (2004) Crosstalk between the EGFR and LIN-12/
Notch pathways in C. elegans vulval development. Science 303: 663–666.
57. Fay DS, Yochem J (2007) The SynMuv genes of Caenorhabditis elegans in vulval
development and beyond. Dev Biol 306: 1–9.
58. Gehlenborg N, O’Donoghue SI, Baliga NS, Goesmann A, Hibbs MA, et al.
(2010) Visualization of omics data for systems biology. Nat Methods 7: S56–S68.
59. Berger SI, Iyengar R (2009) Network analyses in systems pharmacology.
Bioinformatics 25: 2466–2472.
60. Gao Z, Li H, Zhang H, Liu X, Kang L, et al. (2008) PDTD: a web-accessible
protein database for drug target identification. BMC Bioinformatics 9: 104.
61. Fabbro D, Ruetz S, Buchdunger E, Cowan-Jacob SW, Fendrich G, et al. (2002)
Protein kinases as targets for anticancer agents: from inhibitors to useful drugs.
Pharmacol Ther 93: 79–98.
62. Yildirim MA, Goh KI, Cusick ME, Barabasi AL, Vidal M (2007) Drug-target
network. Nat Biotechnol 25: 1119–1126.
63. Hopkins AL (2008) Network pharmacology: the next paradigm in drug
discovery. Nat Chem Biol 4: 682–690.
64. Schadt EE, Friend SH, Shaywitz DA (2009) A network view of disease and
compound screening. Nat Rev Drug Discov 8: 286–295.
65. Wist AD, Berger SI, Iyengar R (2009) Systems pharmacology and genome
medicine: a future perspective. Genome Med 1: 11.
Identification of Novel Signaling Pathway Proteins
PLoS ONE | www.plosone.org 13 May 2011 | Volume 6 | Issue 5 | e19240